DR. KATHERINE GORDON TO JOIN BIOTIME'S BOARD OF DIRECTORS

BERKELEY, CA --June 26, 2001--BioTime, Inc. (AMEX:BTX - news) announced today that Dr. Katherine Gordon has been elected to its board of directors. Dr. Gordon is the president of Apollo BioPharmaceutics, Inc., a company founded in 1992 to develop unique products for central nervous system disorders. Apollo has a strategic alliance with American Home Products Corp. for estrogen treatment in Alzheimer's Disease.

``My selection as a member of BioTime's board of directors allows me greater participation in a company whose current emphasis on critical care and geriatric medicine closely matches my own interests in these fields,'' said Dr. Gordon.

``We are very pleased with the addition of Dr. Gordon to our board of directors,'' said Dr. Paul Segall, BioTime board chairman and chief executive officer. ``She has a distinguished career both in corporate management and biomedical research. Her leadership in the development of therapeutics for brain aging, as well as in embryology and molecular genetics, fits very well with our plans to create new products in critical care and geriatric medicine.''

Prior to 1992, Dr. Gordon was an Associate Director of Genzyme Corporation, where she launched a business unit which derives therapeutic proteins, such as ``clot buster'' drugs for heart patients, from the milk of transgenic animals (animals to which particular genes have been transferred). In 1993, this department was spun off from Genzyme as a free-standing company known as Genzyme Transgenics Corporation (listed on the Nasdaq National Market as GZTC). Dr. Gordon was at Integrated Genetics (acquired by Genzyme) and Genzyme from 1984 to 1991. She has 20 years of experience in mammalian genetics/molecular biology, a field in which she is a noted pioneer in human gene transfer. She has numerous peer-reviewed publications and issued patents to her credit.

BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com.

The matters discussed in this press release include forward-looking statements, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products; the availability of ingredients used in BioTime products; and the availability of reimbursement for the cost of BioTime products (and related treatment) from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission.

--------------------------------------------------------------------------------
Contact:

BioTime, Inc.
Victoria Bellport, 510/845-9535
Malkie Bernheim, 212/752-8338